Macitentan; Tadalafil Patent Expiration
Macitentan; Tadalafil was first introduced by Actelion Pharmaceuticals Us Inc
Macitentan; Tadalafil Patents
Given below is the list of patents protecting Macitentan; Tadalafil, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Opsynvi | US8268847 | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor | Apr 18, 2029 | Actelion |
| Opsynvi | US10946015 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | Sep 11, 2026 | Actelion |
| Opsynvi | US7094781 | Sulfamides and their use as endothelin receptor antagonists | Dec 05, 2025 | Actelion |
Macitentan; Tadalafil's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List